Core Technology Platform
NanoMab
Strength of NanoMab
One-tenth the size of classical monoclonal antibodies (MoAbs)
Superior stability enables versatile modularity without CMC/Toxicity concerns
Conventional Antibody
NanoMab
Stability
Multi-specific NanoMAb
| Physicochemical properties | scFv* | NanoMab |
|---|---|---|
| Size | 30-35 KDa 2×3nm | 12-15 KDa 1×2.5nm |
| Half-life in blood | <1h | <<1h |
| Water solubility | + | +++ |
| Aggregation | ++ | - |
| Stability under harsh condition | + | +++ |
| Tissue penetration | + | ++ |
| Paratope diversity | + | ++ |
| Easy engineering; enhance affinity | + | ++ |
*Single-Chain Fragment Variable
Modified from Front Immunol. 2023; 14: 1303353.
NanoMab
High-Caliber Proprietary Platform for Multi-specific I.O. Drugs
World-competitive
NanoMab platform
-
Own Alpaca Farm
-
Immunized Libraries from alpaca
- From alpacas immunized with target proteins
- > 30 proprietary immune libraries: size > 108
-
NFP technology
No-False-Positive
-
phage display
- High fidelity, high-throughput multiplex screening without false positivity
- HERA panning and λ panning system
- Cloning within 9 weeks
-
High-throughput validation technology
-
More than 30 years of experiences in Immunology
- - Nature Rev. Immunol 2004
- - Nature Nanotechnology 2011
-
Multi-specific, versatile Platforms
-
- mRNA formulation
- PROTAC formulation
- RPT formulation